Towa Pharmaceutical : FY2022 Supplementary Material of Financial Results (1.2M/42P)
May 15, 2023 at 04:08 am EDT
Share
Supplementary material for the financial results for
the year ending March 31, 2023
May 2023
(Stock code: 4553)
2023
Notes to and summary of the disclosure of financial results for 2023/03
Notes
Sunsho Pharmaceutical, which became a subsidiary in March 2022, has been included in the consolidated balance sheets since 2022/03 and the consolidated statements of income since 2023/03.
Due to the change in the fiscal year end of Towa HD and Sunsho Pharmaceutical, the consolidated fiscal year of both companies for the fiscal year ending March 31, 2023 is 15 months from January 1, 2022 to March 31, 2023.
The actual figures for Towa HD and Sunsho Pharmaceutical for the fiscal year ending March 31, 2023, adjusted from 15 months to 12 months, are disclosed as a reference for comparison purposes.
When comparing with the actual figures for the period ending March 31, 2022, the actual results for the period from January to December 2022 (" Adjusted Results (i)") are used.
When comparing with the planned figures for the fiscal year ending March 31, 2024, the actual results for the period from April 2022 to March 2023 ("Adjusted Results (ii)") are used.
On May 10, we announced a revision to our full-year consolidated earnings forecast for the fiscal year ending March 31, 2023
On May 15, we announced a revision to our mid-term consolidated earnings forecast of the 5th Mid-term Business Plan 2021-2023「PROACTIVEⅡ」.
2023
1
Notes to and summary of the disclosure of financial results for 2023/03
Summary
●Both actual and adjusted results increased in sales and decreased in income from the previous fiscal year, mainly due to the inclusion of Sunsho Pharmaceutical in the scope of consolidation from the fiscal year ending March 31, 2023.
2023/03 Actual Results
2023/03 Adjusted Results (i)
2022/03
Fiscal period
(Overseas & Sunsho 15 months,
(Overseas & Sunsho 12 months,
Actual Results
January 2022 - March 2023）
January 2022 - December 2022 )
Item
(JPY billion)
YOY change (%)
(JPY billion)
YOY change (%)
(JPY billion)
Net sales
208.9
+ 26.2
192.0
+ 15.9
165.6
Operating
5.5
- 71.2
6.8
- 64.7
19.2
profit
●Production volume (Non-consolidated; tablets and capsules only)
Approx. 12.9 billion tablets, up approx. 14.2% year on year
●Sales volume (Non-consolidated; tablets and capsules only)
Approx. 11.4 billion tablets, down approx. 2.0% year on year
●Increases in raw material costs and utilities expenses
Raw materials: Increased by several percentage points year on year due to higher resource prices and a weaker yen
Utilities expenses: Increased by approx. 65% year on year
2023
2
Contents
Outline of financial results for 2023/03
Outline of financial results for 2023/03 - Progress rate
Balance sheets, capital expenditure and depreciation
Full-yearplan for 2024/03
2023
3
Contents
1. Outline of financial results for 2023/03
Consolidated
Segment information
Domestic segment
Breakdown
Net sales by supplement year (Non-consolidated) Net sales by distribution channel (Non-consolidated)
Number of customers by customer segment (Non-consolidated) Selling, general and administrative expenses (Domestic segment)
Overseas segment
By region
Sales ratio of products released in the last three years
Approved and new products for 2023/03
Outline of financial results for 2023/03 - Progress rate
Balance sheets, capital expenditure and depreciation
TOWA Pharmaceutical Co. Ltd. published this content on 14 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2023 08:07:08 UTC.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
TOWA PHARMACEUTICAL CO., LTD. 
